Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology.
DOI: 10.1200/JCO.1997.15.2.853 Journal of Clinical Oncology 15, no. 2 (February 01, 1997) 853-9. Published online September 21, 2016. PMID: 9053513
Related Articles
Operationalizing Precision Oncology: The Expanding Role of the Clinical Precision Medicine Oncology Pharmacist
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer
The role of dual checkpoint inhibition in advanced rare/ultra-rare non-epithelial ovarian cancers (NEOCs) is yet to be explored. DART is a prospective, multicenter (1,016 US…
Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials – PubMed
Our data suggest that IO biomarkers should be used in patient selection for ICIs. Prospective studies are warranted.
Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab – PubMed
Comprehensive genomic profiling (CGP) and the subsequent discussions in molecular tumor boards (MTBs) are becoming an integral part of personalized cancer care. The patient with…
Patient rights in precision oncology: right treatment, right time, right dose, right order, right place
Precision oncology has facilitated a transition from a one-size-fits-all to a precise individualized approach. This Comment discusses the broader challenges in the implementation of personalized…
Patient rights in precision oncology: right treatment, right time, right dose, right order, right place
Precision oncology has facilitated a transition from a one-size-fits-all to a precise individualized approach. This Comment discusses the broader challenges in the implementation of personalized…
Gene editing helped a desperately ill baby thrive. Scientists say it could someday treat millions
A baby born with a rare and dangerous genetic disease is thriving after getting an experimental gene editing treatment made just for him.
Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly – PubMed
Discovering the brakes/checkpoints that cancer places on the immune system to prevent being eradicated led to the 2018 Nobel Prize and the development of multiple…